Quantcast
Last updated on April 23, 2014 at 1:22 EDT

Latest Pre-exposure prophylaxis Stories

2012-05-17 23:00:16

"The FDA Decision to approve Truvada* by 19 votes against 3 in the prevention of HIV transmission on May 11 is irresponsible and against Global Public Health Interests," declares Doctor Alain Lafeuillade, Head of the Department of Infectious Diseases in Toulon (France) and Chair of the ISHEID to be held in Marseilles (France) in 6 days. Marseilles, France (PRWEB) May 17, 2012 The recent Truvada* FDA approval for pre-exposure prophylaxis "looks like a non sense in other 'developed'...

2012-05-17 10:25:39

WASHINGTON, May 17, 2012 /PRNewswire/ -- MS -- This summer, more than 25,000 leading scientists, public health experts, policy-makers, community members, and experts in the HIV/AIDS field from around the world will gather in our nation's capital for the International AIDS Society's XIX International AIDS Conference. This gathering provides a vital platform to address the global response to HIV/AIDS and the efforts to overcome barriers that limit access to care, services, prevention tools, and...

2012-05-16 10:58:17

Pre-birth exposure to the anti-HIV drug tenofovir does not adversely affect pregnancy outcomes and does not increase birth defects, growth abnormalities, or kidney problems in infants born to African women who are HIV positive, supporting the use of this drug during pregnancy, according to a study by a team of international researchers published in this week's PLoS Medicine. The researchers led by Diana Gibb from the MRC Clinical Trials Unit in London, UK, analyzed data collected on...

2012-05-14 21:35:05

Truvada alone not sufficient, given adherence and other challenges A drug that has been shown to prevent HIV infection in a significant number of cases must be combined with behavioral approaches if the U.S. health care establishment is to succeed in reducing the spread of the virus, according to the American Psychological Association. "Exclusive reliance on a drug to prevent HIV or any sexually transmitted disease could actually result in a worse outcome if those at risk don't...

2012-05-10 14:22:45

NEW YORK, May 10, 2012 /PRNewswire-USNewswire/ -- AVAC hails the recommendation by an FDA Advisory Committee that emtricitabine/tenofovir disoproxil fumarate (TDF/FTC or Truvada) be approved for use as pre-exposure prophylaxis (PrEP) among sexually active adult men and women. Citing the urgent need for new HIV prevention options to stem HIV infections, AVAC urges the FDA to issue an approval for all men and women at risk, and is calling on public health agencies, governments, advocates and...

2012-05-01 10:25:35

Written Comments to FDA Advisory Committee Cite Compelling Evidence for PrEP and Urgent Need for Every Available Tool to End AIDS NEW YORK, May 1, 2012 /PRNewswire-USNewswire/ -- In public comments submitted this week, a group of 14 leading HIV/AIDS and health organizations stated their support for Food and Drug Administration (FDA) approval of emtricitabine/ tenofovir disoproxil fumarate (TDF/FTC or Truvada®) as pre-exposure prophylaxis (PrEP) to prevent HIV infection in adult...

2012-04-19 06:25:43

RESEARCH TRIANGLE PARK, N.C., April 19, 2012 /PRNewswire-USNewswire/ -- In recognition of her many significant contributions to the field of HIV prevention, FHI 360 Senior Scientist Lut Van Damme, M.D., Ph.D. received a Lifetime Achievement Award this week at the 2012 International Microbicides Conference in Sydney, Australia. (Logo: http://photos.prnewswire.com/prnh/20110706/DC30736LOGO) "FHI 360 congratulates Lut on this well-deserved achievement," said Dr. Albert Siemens, CEO...

2012-04-17 10:38:33

No added HIV risk with hormonal contraceptives, 1 study finds: Results presented at Microbicides 2012 An HIV prevention trial that pre-dates the shift to antiretroviral (ARV)-based approaches is nonetheless helping to answer some of the most relevant and topical questions the field is facing today. More than three years after reporting the primary results of HPTN 035, one of the last trials of the so-called first generation microbicides, researchers from the National Institutes of...

2012-04-17 10:19:17

A once-a-day pill to help prevent HIV infection could significantly reduce the spread of AIDS, but only makes economic sense if used in select, high-risk groups, Stanford University researchers conclude in a new study. The researchers looked at the cost-effectiveness of the combination drug tenofovir-emtricitabine, which was found in a landmark 2010 trial to reduce an individual's risk of HIV infection by 44 percent when taken daily. Patients who were particularly faithful about taking the...

2012-04-16 21:35:58

Researchers, activists and funders are meeting this week in Sydney to discuss the state of HIV prevention research. The biennial International Microbicides Conference, which was opened on Sunday evening by the Honorable Tanya Plibersek MP, Australian Minster of Health, is taking place amid renewed optimism about development and delivery of new HIV prevention options with the potential for ending the AIDS epidemic, including anti-retroviral based microbicides and pre-exposure prophylaxis...